ICP
PACB icon

Interchange Capital Partners’s Pacific Biosciences PACB Stock Holding History

Interchange Capital Partners’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.3K Buy
21,400
+4,587
+27% +$8.21K 0.01% 280
2025
Q4 		$31.4K Sell
16,813
-982
-6% -$1.89K 0.01% 423
2025
Q3 		$22.8K Sell
17,795
-512
-3% -$693 ﹤0.01% 365
2025
Q2 		$22.7K Sell
18,307
-5,256
-22% -$6.07K 0.01% 280
2025
Q1 		$27.8K Sell
23,563
-6,433
-21% -$9.87K 0.01% 270
2024
Q4 		$52.9K Buy
29,996
+1,034
+4% +$2.02K 0.02% 252
2024
Q3 		$49.2K Sell
28,962
-2,237
-7% -$3.67K 0.02% 269
2024
Q2 		$42.7K Buy
31,199
+2,558
+9% +$5.17K 0.02% 271
2024
Q1 		$114K Buy
28,641
+9,932
+53% +$58.2K 0.08% 167
2023
Q4 		$184K Buy
18,709
+1,991
+12% +$16.3K 0.14% 148
2023
Q3 		$140K Buy
16,718
+4,058
+32% +$46.4K 0.11% 147
2023
Q2 		$168K Buy
+12,660
New +$154K 0.13% 147
2022
Q3 		– Sell
-10,506
Closed -$46K – 167
2022
Q2 		$46K Sell
10,506
-713
-6% -$4.33K 0.05% 153
2022
Q1 		$102K Buy
+11,219
New +$129K 0.1% 155

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Interchange Capital Partners's PACB Position: Q1 2026 in Review

Interchange Capital Partners increased its Pacific Biosciences (PACB) stake by 27% in Q1 2026, buying an estimated $8.21K and bringing the position to 21,400 shares worth $25.3K. The position accounts for 0.01% of the portfolio, ranked #280.

Interchange Capital Partners first reported a position in PACB in Q1 2022 and has held it in 14 quarters since. The position peaked at $184K in Q4 2023. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Interchange Capital Partners held 21,400 shares of Pacific Biosciences worth $25.3K as of Q1 2026.
  • Interchange Capital Partners bought 4,587 Pacific Biosciences shares in Q1 2026, an estimated $8.21K.
  • Pacific Biosciences made up 0.01% of Interchange Capital Partners's portfolio in Q1 2026, its #280 holding.
  • Interchange Capital Partners first reported a position in Pacific Biosciences in Q1 2022 and has held it in 14 quarters since.
  • Interchange Capital Partners's Pacific Biosciences position peaked at $184K in Q4 2023.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Interchange Capital Partners's 13F filing for Q1 2026, filed 24 Apr 2026.